Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Milestone Scientific Inc (MLSS)
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
$0.33+8.26%
Close 2026-11-04 · 1-day change
AMEXHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for MLSS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve cash flow from operations to positive territory | Milestone is improving cash flow from operations, up $313K from last quarter. | Recovered | cash from operations falls below zero next year | Cash from operations: $-585,127 FY2026-Q2; GAAP. Published target: >= $86,842 in cash from operations. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-585,127 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth and execution story, not an established durable compounder. The multi-year thesis is in a watch state: revenue has risen, but losses and fragile earnings quality leave the business setup uncertain.
The valuation model shows MLSS at a premium to peers, while its expectations gap is negative, meaning expectations look demanding relative to the evidence. The pricing signal is marked as justified because weak execution quality is recognized, but the evidence does not show that all of the business risks are reflected.
Near term, revenue increased from $2.06 million in 2025-Q4 to $2.84 million in 2026-Q2, while operating income remained negative at $1.06 million in 2026-Q2. Board changes and M&A efforts are underway, but private placements and fluctuating operating cash flow show that financial improvement remains limited; weaker jobs data could also weigh on cyclical names.
Over the next one to three years, the thesis depends on whether governance changes and M&A activity translate into stronger financial performance, rather than continued losses and reliance on new capital. Healthcare sector momentum is another swing factor: continued strong results from bellwethers could support the backdrop, while misses or lower guidance could weaken it.
The multi-year view is uncertain: revenue growth and a supportive sector backdrop are offset by losses, fragile execution, and a valuation premium to peers. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Although improving cash flow from operations has been a stated priority historically, it was not explicitly restated in the current disclosures. Cash from operations fluctuated significantly, improving from -$1.76M in 2025-Q2 to $86.8K in 2026-Q1, then declining to -$585K in 2026-Q2, indicating limited sustained progress on this front.
Stabilize management and board after recent changes | New board members may help stabilize management. | Improving | Further key management departures or instability occur | Board restructured with 2 new independent directors and stable CEO; no further departures since June 2026 Board restructured in June 2026 with new independent directors; no further management departures or instability reported since. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve about 17% revenue growth next year | It is growing revenue about 17% next year. | Improving | revenue growth falls below 10% next year | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.03 → $-0.04 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-25 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-26 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-27 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-28 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-29 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-07-30 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-07-31 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-01 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-02 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-03 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-04 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-05 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-06 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-07 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-08 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-09 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-10 | $-0.04 | $11,250,500 | 2 / 2 |
| 2026-08-12 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-13 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-14 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-15 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-16 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-17 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-18 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-19 | $-0.03 | $11,250,500 | 2 / 2 |
| 2026-08-20 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-21 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-22 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-23 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-24 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-25 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-26 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-27 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-28 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-29 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-30 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-08-31 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-01 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-02 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-03 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-04 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-05 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-06 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-07 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-08 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-09 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-10 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-11 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-12 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-13 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-14 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-15 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-16 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-17 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-18 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-19 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-20 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-21 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-22 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-23 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-24 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-25 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-26 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-27 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-28 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-29 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-09-30 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-01 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-02 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-03 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-04 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-05 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-06 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-07 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-08 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-09 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-10 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-11 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-12 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-13 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-14 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-15 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-16 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-17 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-18 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-19 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-20 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-21 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-22 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-23 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-24 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-25 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-26 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-27 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-28 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-29 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-30 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-10-31 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-11-01 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-11-02 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-11-03 | $-0.04 | $11,350,500 | 2 / 2 |
| 2026-11-04 | $-0.04 | $11,350,500 | 2 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.